ACEI treatment was associated with higher plasma total NO concentration (24.66 µmol/l) compared to ARB (18.57 µmol/l) and non-ACE/ARB groups (16.83 µmol/l, P=0.0127), with no difference in FMD.
Cross-Sectional (n=177)
Does ACEI or ARB treatment improve nitric oxide-dependent endothelial function and alter bradykinin receptor gene expression in cardiovascular patients?
ACEI treatment, but not ARB, enhances total nitrite/nitrate concentration and alters bradykinin receptor expression in PBMC, though it does not translate to differences in flow-mediated dilation.
Absolute Event Rate: 24.66% vs 16.83%
p-value: p=0.0127
Summary: Background: Angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are widely used as a first-line therapy for the treatment of cardiovascular disease. Here, ACEI modulate the bradykinin receptor (BDKRB1 and BDKRB2) system and NO-dependent endothelial function, thus determining cardiovascular health and regenerative arteriogenesis. The current study aims at evaluating nitric oxide-dependent endothelial function, and gene expression of bradykinin receptors in peripheral blood mononuclear cells (PBMC) from patients with ACEI or ARB treatment. Patients and methods: The WalkByLab has been established to screen cardiovascular patients for peripheral artery disease and coronary artery disease. In total 177 patients from WalkByLab with heterogenous disease and risk status were randomly selected, divided according to their medication history into the following groups: 1. ACEI group, 2. ARB group or 3. non-ACE/ARB group. Total plasma nitrite/nitrate (NO) levels were measured, endothelial function was evaluated by assessing flow meditated dilation (FMD). PBMC were isolated from peripheral whole blood, and gene expression (qRT-PCR) of bradykinin receptors and angiotensin converting enzyme were assessed. Results: Plasma total NO concentration in the ACEI group (24.66±16.28, µmol/l) was increased as compared to the ARB group (18.57±11.58, µmol/l, P=0.0046) and non-ACE/ARB group (16.83±8.64, µmol/l, P=0.0127) in patients between 40 to 90 years of age. However, FMD values (%) in the ACEI group (7.07±2.40, %) were similar as compared to the ARB (6.35±2.13, %) and non-ACE/ARB group (6.51±2.15, %), but significantly negatively correlated with age. Interestingly, BDKRB1 mRNA level was significantly higher and BDKRB2 mRNA level lower in the ACEI group (BDKRB1 3.88-fold±1.05, BDKRB2 0.22-fold±0.04) as compared to the non-ACE/ARB group (BDKRB1 1.00-fold±0.39, P<0.0001, BDKRB2 1.00-fold±0.45, P=0.0136). Conclusions: ACEI treatment enhances total nitrite/nitrate concentration, furthermore, upregulates BDKRB1 in PBMC, but downregulates BDKRB2 mRNA expression. FMD is a strong determinant of vascular aging and is sensitive to underlying heterogenous cardiovascular diseases.
Li et al. (Wed,) conducted a cross-sectional in Peripheral artery disease and coronary artery disease (n=177). ACEI or ARB vs. Non-ACE/ARB was evaluated on Plasma total NO concentration (p=0.0127). ACEI treatment was associated with higher plasma total NO concentration (24.66 µmol/l) compared to ARB (18.57 µmol/l) and non-ACE/ARB groups (16.83 µmol/l, P=0.0127), with no difference in FMD.